{"id":{"repo_id":"aachen","oai_identifier":"oai:publications.rwth-aachen.de:51272"},"canonical_url":"https://search.dev.ndltd.org/etd/aachen/oai:publications.rwth-aachen.de:51272","repository":{"repo_id":"aachen","name":"RWTH Aachen University","base_url":"https://publications.rwth-aachen.de/oai2d"},"display":{"title":"Kardioprotektion durch Veränderung des Zytoskelettes im Langendorff-Hypoxie-Modell der Ratte","abstract":"In this work changes of the cytoskeleton of cardiomyocytes are examined on the basis of isolated, perfused rat's hearts by the application of the different drugs which are also combined together. The effects of different drugs on the cytoskeleton, before all in the ischaemic phase, are examined on a biochemical basis with the help of the creatine kinase release and on a histological basis with the help of the apoptotic properties of the myocytes. Carvedilol is a beta blocker with alpha-receptor blocking quality and, in addition, antioxidative and antiapoptotic properties. As a comparison are used the beta blocker Propranolol and the Carvedilol analogon BM 91.0228, which owns in comparison to the mother's substance Carvedilol, no significant beta-blocking qualities. Besides two the cytoskeleton influencing drugs, Taxol and Vinblastin are also examined. Each of the five substances mentioned above are individually evaluated in regard of the ceratine kinase release and die apoptotic properties. Then Carvedilol, BM 91.0228 and Propranolol are used in combination with Taxol and Vinblastin to gather additional results during hypoxic conditions. Concerning the activity of the creatine kinase Carvedilol, Propranolol and Taxol, but not BM 91.0228 led, to a diminished emission of the creatine kinase and Taxol showed concerning this the strongest effect. Vinblastin also pointed, like BM 91.0228, no reduction of the creatine kinase. But the combination of Vinblatin and Carvedilol showed a significant decreased release of the creatine kinase during hypoxic conditions. The combination of Taxol and Carvedilol led to the significantly strongest reduction of the creatine kinase emission. Carvedilol, BM 91.0228 and Taxol could lower the apoptotic cell rate up to 50% in comparison to the control group. Vinblastin and Propranolol showed no effect in regard to the apoptosis. The results of this work show that the cytoskeleton plays an important role with the enzyme release during the hypoxic-phase. The increase of the cardioprotective effect of the Carvedilols by combination with Taxol shows that these both drugs could play an important role in the therapy of the cardiac insufficiency in future.","abstract_html":"In this work changes of the cytoskeleton of cardiomyocytes are examined on the basis of isolated, perfused rat's hearts by the application of the different drugs which are also combined together. The effects of different drugs on the cytoskeleton, before all in the ischaemic phase, are examined on a biochemical basis with the help of the creatine kinase release and on a histological basis with the help of the apoptotic properties of the myocytes. Carvedilol is a beta blocker with alpha-receptor blocking quality and, in addition, antioxidative and antiapoptotic properties. As a comparison are used the beta blocker Propranolol and the Carvedilol analogon BM 91.0228, which owns in comparison to the mother's substance Carvedilol, no significant beta-blocking qualities. Besides two the cytoskeleton influencing drugs, Taxol and Vinblastin are also examined. Each of the five substances mentioned above are individually evaluated in regard of the ceratine kinase release and die apoptotic properties. Then Carvedilol, BM 91.0228 and Propranolol are used in combination with Taxol and Vinblastin to gather additional results during hypoxic conditions. Concerning the activity of the creatine kinase Carvedilol, Propranolol and Taxol, but not BM 91.0228 led, to a diminished emission of the creatine kinase and Taxol showed concerning this the strongest effect. Vinblastin also pointed, like BM 91.0228, no reduction of the creatine kinase. But the combination of Vinblatin and Carvedilol showed a significant decreased release of the creatine kinase during hypoxic conditions. The combination of Taxol and Carvedilol led to the significantly strongest reduction of the creatine kinase emission. Carvedilol, BM 91.0228 and Taxol could lower the apoptotic cell rate up to 50% in comparison to the control group. Vinblastin and Propranolol showed no effect in regard to the apoptosis. The results of this work show that the cytoskeleton plays an important role with the enzyme release during the hypoxic-phase. The increase of the cardioprotective effect of the Carvedilols by combination with Taxol shows that these both drugs could play an important role in the therapy of the cardiac insufficiency in future.","abstract_has_math":false,"creators":["Dannemann, Oliver"],"institution":"Publikationsserver der RWTH Aachen University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":["Schwarz, Ernst Rüdiger"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2009,"date_issued":"2009","date_published":"2009","updated_at":"2026-07-30T19:40:33Z","subjects":["info:eu-repo/classification/ddc/610","Myokardprotektion","Carvedilol","Apoptosis","Kreatinkinase","Medizin","mycardial protection","creatine kinase"],"languages":["ger"],"rights":["info:eu-repo/semantics/openAccess"],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier","label":"Identifier","values":["https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-113582%22"],"render_values":[{"text":"https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-113582%22","href":"https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-113582%22","code":true}]}]},"links":{"outbound_url":"https://publications.rwth-aachen.de/record/51272","outbound_label":"Repository record","outbound_source":"dc:identifier"},"source_record":{"url":"https://publications.rwth-aachen.de/oai2d?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Apublications.rwth-aachen.de%3A51272","prefix":"oai_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Schwarz, Ernst Rüdiger"]},{"key":"dc:creator","label":"Author","values":["Dannemann, Oliver"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:coverage","label":"Dc Coverage","values":["DE"]},{"key":"dc:date","label":"Dc Date","values":["2009"]},{"key":"dc:publisher","label":"Institution","values":["Publikationsserver der RWTH Aachen University"]},{"key":"dc:relation","label":"Dc Relation","values":["info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:82-opus-29235"]},{"key":"dc:type","label":"Dc Type","values":["info:eu-repo/semantics/doctoralThesis","info:eu-repo/semantics/publishedVersion"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["info:eu-repo/classification/ddc/610","Myokardprotektion","Carvedilol","Apoptosis","Kreatinkinase","Medizin","mycardial protection","creatine kinase"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["ger"]},{"key":"dc:rights","label":"Dc Rights","values":["info:eu-repo/semantics/openAccess"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://publications.rwth-aachen.de/record/51272","https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-113582%22"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["In this work changes of the cytoskeleton of cardiomyocytes are examined on the basis of isolated, perfused rat's hearts by the application of the different drugs which are also combined together. The effects of different drugs on the cytoskeleton, before all in the ischaemic phase, are examined on a biochemical basis with the help of the creatine kinase release and on a histological basis with the help of the apoptotic properties of the myocytes. Carvedilol is a beta blocker with alpha-receptor blocking quality and, in addition, antioxidative and antiapoptotic properties. As a comparison are used the beta blocker Propranolol and the Carvedilol analogon BM 91.0228, which owns in comparison to the mother's substance Carvedilol, no significant beta-blocking qualities. Besides two the cytoskeleton influencing drugs, Taxol and Vinblastin are also examined. Each of the five substances mentioned above are individually evaluated in regard of the ceratine kinase release and die apoptotic properties. Then Carvedilol, BM 91.0228 and Propranolol are used in combination with Taxol and Vinblastin to gather additional results during hypoxic conditions. Concerning the activity of the creatine kinase Carvedilol, Propranolol and Taxol, but not BM 91.0228 led, to a diminished emission of the creatine kinase and Taxol showed concerning this the strongest effect. Vinblastin also pointed, like BM 91.0228, no reduction of the creatine kinase. But the combination of Vinblatin and Carvedilol showed a significant decreased release of the creatine kinase during hypoxic conditions. The combination of Taxol and Carvedilol led to the significantly strongest reduction of the creatine kinase emission. Carvedilol, BM 91.0228 and Taxol could lower the apoptotic cell rate up to 50% in comparison to the control group. Vinblastin and Propranolol showed no effect in regard to the apoptosis. The results of this work show that the cytoskeleton plays an important role with the enzyme release during the hypoxic-phase. The increase of the cardioprotective effect of the Carvedilols by combination with Taxol shows that these both drugs could play an important role in the therapy of the cardiac insufficiency in future."]},{"key":"dc:source","label":"Dc Source","values":["Aachen : Publikationsserver der RWTH Aachen University 69 S. : graph. Darst. (2009). = Aachen, Techn. Hochsch., Diss., 2009"]},{"key":"dc:title","label":"Title","values":["Kardioprotektion durch Veränderung des Zytoskelettes im Langendorff-Hypoxie-Modell der Ratte"]}]}],"canonical_facts":{"dc:contributor":["Schwarz, Ernst Rüdiger"],"dc:coverage":["DE"],"dc:creator":["Dannemann, Oliver"],"dc:date":["2009"],"dc:description":["In this work changes of the cytoskeleton of cardiomyocytes are examined on the basis of isolated, perfused rat's hearts by the application of the different drugs which are also combined together. The effects of different drugs on the cytoskeleton, before all in the ischaemic phase, are examined on a biochemical basis with the help of the creatine kinase release and on a histological basis with the help of the apoptotic properties of the myocytes. Carvedilol is a beta blocker with alpha-receptor blocking quality and, in addition, antioxidative and antiapoptotic properties. As a comparison are used the beta blocker Propranolol and the Carvedilol analogon BM 91.0228, which owns in comparison to the mother's substance Carvedilol, no significant beta-blocking qualities. Besides two the cytoskeleton influencing drugs, Taxol and Vinblastin are also examined. Each of the five substances mentioned above are individually evaluated in regard of the ceratine kinase release and die apoptotic properties. Then Carvedilol, BM 91.0228 and Propranolol are used in combination with Taxol and Vinblastin to gather additional results during hypoxic conditions. Concerning the activity of the creatine kinase Carvedilol, Propranolol and Taxol, but not BM 91.0228 led, to a diminished emission of the creatine kinase and Taxol showed concerning this the strongest effect. Vinblastin also pointed, like BM 91.0228, no reduction of the creatine kinase. But the combination of Vinblatin and Carvedilol showed a significant decreased release of the creatine kinase during hypoxic conditions. The combination of Taxol and Carvedilol led to the significantly strongest reduction of the creatine kinase emission. Carvedilol, BM 91.0228 and Taxol could lower the apoptotic cell rate up to 50% in comparison to the control group. Vinblastin and Propranolol showed no effect in regard to the apoptosis. The results of this work show that the cytoskeleton plays an important role with the enzyme release during the hypoxic-phase. The increase of the cardioprotective effect of the Carvedilols by combination with Taxol shows that these both drugs could play an important role in the therapy of the cardiac insufficiency in future."],"dc:identifier":["https://publications.rwth-aachen.de/record/51272","https://publications.rwth-aachen.de/search?p=id:%22RWTH-CONV-113582%22"],"dc:language":["ger"],"dc:publisher":["Publikationsserver der RWTH Aachen University"],"dc:relation":["info:eu-repo/semantics/altIdentifier/urn/urn:nbn:de:hbz:82-opus-29235"],"dc:rights":["info:eu-repo/semantics/openAccess"],"dc:source":["Aachen : Publikationsserver der RWTH Aachen University 69 S. : graph. Darst. (2009). = Aachen, Techn. Hochsch., Diss., 2009"],"dc:subject":["info:eu-repo/classification/ddc/610","Myokardprotektion","Carvedilol","Apoptosis","Kreatinkinase","Medizin","mycardial protection","creatine kinase"],"dc:title":["Kardioprotektion durch Veränderung des Zytoskelettes im Langendorff-Hypoxie-Modell der Ratte"],"dc:type":["info:eu-repo/semantics/doctoralThesis","info:eu-repo/semantics/publishedVersion"]},"updated_at":"2026-07-30T19:40:33Z"}